Beam Therapeutics· @BeamTx · X·· 3 小时前AI 评分38
AI 导读
Beam将在第33届欧洲基因与细胞治疗学会（ESGCT）年会上，公布正在进行的评估BEAM-301治疗Ia型糖原贮积病（GSDIa）的1/2期临床试验的初步数据。
正文
Beam will present initial data from the ongoing Phase 1/2 clinical trial evaluating BEAM-301 for the treatment of glycogen storage disease type Ia (GSDIa) at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT).
来源：Beam Therapeutics · x.com